Gynecologic Oncology

Papers
(The H4-Index of Gynecologic Oncology is 41. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
Variations in incidence and mortality rates of endometrial cancer at the global, regional, and national levels, 1990–2019102
Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002)99
Outcomes of enhanced recovery after surgery (ERAS) in gynecologic oncology – A systematic review and meta-analysis.85
Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer85
Molecular subtypes of clear cell carcinoma of the endometrium: Opportunities for prognostic and predictive stratification77
Low-grade serous ovarian cancer: State of the science74
Clinical assays for assessment of homologous recombination DNA repair deficiency67
Stromal POSTN induced by TGF-β1 facilitates the migration and invasion of ovarian cancer67
Vulvar cancer subclassification by HPV and p53 status results in three clinically distinct subtypes66
Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer57
Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer55
Uterine serous carcinoma54
Exosomal microRNAs and exosomal long non-coding RNAs in gynecologic cancers53
Uterine carcinosarcoma: Contemporary clinical summary, molecular updates, and future research opportunity53
Validation of American College of Radiology Ovarian-Adnexal Reporting and Data System Ultrasound (O-RADS US): Analysis on 1054 adnexal masses52
Recurrence rate after loop electrosurgical excision procedure (LEEP) and laser Conization: A 5-year follow-up study51
Histopathological characterization of ProMisE molecular groups of endometrial cancer51
FIGO 2018 staging criteria for cervical cancer: Impact on stage migration and survival50
Second-line lenvatinib in patients with recurrent endometrial cancer50
Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial49
Minimally invasive surgery versus laparotomy for radical hysterectomy in the management of early-stage cervical cancer: Survival outcomes49
PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer48
Avelumab in combination with and/or following chemotherapy vs chemotherapy alone in patients with previously untreated epithelial ovarian cancer: Results from the phase 3 javelin ovarian 100 trial47
Prognostic relevance of the molecular classification in high-grade endometrial cancer for patients staged by lymphadenectomy and without adjuvant treatment47
Gynecologic cancer in pregnancy47
Predictive biomarkers of platinum and taxane resistance using the transcriptomic data of 1816 ovarian cancer patients46
Endometrial cancer: A society of gynecologic oncology evidence-based review and recommendations46
Therapeutic options for mucinous ovarian carcinoma46
Clear cell carcinoma of the ovary: Epidemiology, pathological and biological features, treatment options and clinical outcomes45
Trends and age-period-cohort effects on mortality of the three major gynecologic cancers in China from 1990 to 2019: Cervical, ovarian and uterine cancer45
Should endometrial biopsy under direct hysteroscopic visualization using the grasp technique become the new gold standard for the preoperative evaluation of the patient with endometrial cancer?44
Complete pathological response following levonorgestrel intrauterine device in clinically stage 1 endometrial adenocarcinoma: Results of a randomized clinical trial44
Artificial intelligence-assisted cytology for detection of cervical intraepithelial neoplasia or invasive cancer: A multicenter, clinical-based, observational study44
Short-term organoid culture for drug sensitivity testing of high-grade serous carcinoma43
Mismatch repair-deficiency specifically predicts recurrence of atypical endometrial hyperplasia and early endometrial carcinoma after conservative treatment: A multi-center study42
Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract42
An integrated molecular profile of endometrioid ovarian cancer42
Harnessing natural killer cells for the treatment of ovarian cancer42
Genomic profiling of BCOR-rearranged uterine sarcomas reveals novel gene fusion partners, frequent CDK4 amplification and CDKN2A loss41
Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial41
Gestational trophoblastic neoplasia lethality among Brazilian women: A retrospective national cohort study41
0.065780162811279